fiveonefour | $17,000,000 | (Sep 5, 2025)
Sesh Products | $40,000,000 | (Sep 5, 2025)
Pointsville | Undisclosed Amount | (Sep 5, 2025)
Certified by Founder
Lodge
eGenesis, Inc.
start up
United States
- Cambridge, MA
- 04/09/2024
- Series B
- $191,000,000
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
- Industry Biotechnology Research
- Website https://egenesisbio.com/
- LinkedIn https://www.linkedin.com/company/egenesisbio/
Augment | $85,000,000 | (Sep 5, 2025)
Plural(US) | $7,000,000 | (Sep 5, 2025)
Hello Patient | $22,500,000 | (Sep 5, 2025)
Euclid Power | $20,000,000 | (Sep 5, 2025)
Lead | $70,000,000 | (Sep 5, 2025)
Pave Finance | $14,000,000 | (Sep 5, 2025)
throxy (yc x25) | $6,200,000 | (Sep 5, 2025)
Human Behavior (YC X25) | $5,000,000 | (Sep 5, 2025)
FlexifyMe | $2,400,000 | (Sep 5, 2025)